期刊
NUTRIENTS
卷 14, 期 23, 页码 -出版社
MDPI
DOI: 10.3390/nu14235091
关键词
cardiocerebrovascular diseases; fatty acids; alpha linolenic acid; Alzheimer's disease; Alzheimer's dementia; vascular cognitive impairment; blood-brain barrier
资金
- Innovative Research Center (ARC, Sheba)
Cognitive decline in Alzheimer's disease is primarily attributed to protein deposits, but growing evidence suggests that brain lipids and blood-brain barrier dysfunction also play a crucial role. This study investigates the relationship between ApoE4 genotype and altered fatty acid composition in the BBB, and explores the potential therapeutic role of alpha linolenic acid in improving BBB function, particularly in ApoE4 carriers.
Cognitive decline, the primary clinical phenotype of Alzheimer's disease (AD), is currently attributed mainly to amyloid and tau protein deposits. However, a growing body of evidence is converging on brain lipids, and blood-brain barrier (BBB) dysfunction, as crucial players involved in AD development. The critical role of lipids metabolism in the brain and its vascular barrier, and its constant modifications particularly throughout AD development, warrants investigation of brain lipid metabolism as a high value therapeutic target. Yet, there is limited knowledge on the biochemical and structural roles of lipids in BBB functionality in AD. Within this framework, we hypothesize that the ApoE4 genotype, strongly linked to AD risk and progression, may be related to altered fatty acids composition in the BBB. Interestingly, alpha linolenic acid (ALA), the precursor of the majoritarian brain component docosahexaenoic acid (DHA), emerges as a potential novel brain savior, acting via BBB functional improvements, and this may be primarily relevant to ApoE4 carriers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据